Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has ...

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a ...

Sun Pharmaceutical Industries Ltd has launched LEQSELVI (deuruxolitinib) 8 mg tablets, a new treatment for severe alopecia ...

"The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," said Richard Ascroft, CEO, ...

Mumbai: Sun Pharmaceutical Industries Limited has announced the launch of LEQSELVI (deuruxolitinib) 8 mg tablets in the U.S.

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for ...

Sun Pharmaceutical Industries has reached a settlement with Incyte Corporation regarding the Leqselvi drug, used for severe ...

Sun Pharmaceutical Industries announced LEQSELVI (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the U.S. LEQSELVI is indicated ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

Alumni Nicole Friedland (Merrill ’89, community studies) and Brett King (Crown ’92, chemistry) both spoke at the National ...

Over a mean follow-up of 566 days, all-cause mortality rates significantly favored those with ASDs compared with non-ASD ...

LEQSELVI has shown rapid results in clinical trials, with one-third of patients regaining nearly full scalp hair by Week 24.